Fate Therapeutics Valuation
| FATE Stock | USD 1.19 0.02 1.65% |
Today, the firm appears to be overvalued. Fate Therapeutics shows a prevailing Real Value of $0.98 per share. The current price of the firm is $1.19. Our model computes the value of Fate Therapeutics from reviewing the firm fundamentals such as Operating Margin of (19.95) %, shares outstanding of 115.35 M, and Shares Owned By Insiders of 1.90 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Fate Therapeutics' valuation include:
Price Book 0.5865 | Enterprise Value | Enterprise Value Ebitda (2.59) | Price Sales 19.2335 | Enterprise Value Revenue 0.1533 |
Overvalued
Today
Please note that Fate Therapeutics' price fluctuation is extremely dangerous at this time. Calculation of the real value of Fate Therapeutics is based on 3 months time horizon. Increasing Fate Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Fate stock is determined by what a typical buyer is willing to pay for full or partial control of Fate Therapeutics. Since Fate Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Fate Stock. However, Fate Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.19 | Real 0.98 | Target 4.94 | Hype 1.19 | Naive 1.2 |
The real value of Fate Stock, also known as its intrinsic value, is the underlying worth of Fate Therapeutics Company, which is reflected in its stock price. It is based on Fate Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Fate Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Fate Therapeutics helps investors to forecast how Fate stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Fate Therapeutics more accurately as focusing exclusively on Fate Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Fate Therapeutics' intrinsic value based on its ongoing forecasts of Fate Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Fate Therapeutics' closest peers. If more than one evaluation category is relevant for Fate Therapeutics we suggest using both methods to arrive at a better estimate.
Fate Therapeutics Cash |
|
Fate Therapeutics Total Value Analysis
Fate Therapeutics is currently anticipated to have valuation of 1.09 M with market capitalization of 137.27 M, debt of 85.27 M, and cash on hands of 568.85 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Fate Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.09 M | 137.27 M | 85.27 M | 568.85 M |
Fate Therapeutics Investor Information
About 79.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.59. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fate Therapeutics recorded a loss per share of 1.33. The entity had not issued any dividends in recent years. Based on the key indicators related to Fate Therapeutics' liquidity, profitability, solvency, and operating efficiency, Fate Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Fate Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Fate Therapeutics has an asset utilization ratio of 3.09 percent. This indicates that the Company is making $0.0309 for each dollar of assets. An increasing asset utilization means that Fate Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Fate Therapeutics Profitability Analysis
Based on Fate Therapeutics' profitability indicators, Fate Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Fate Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2011-12-31 | Previous Quarter -34.1 M | Current Value -32.2 M | Quarterly Volatility 22.2 M |
For Fate Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Fate Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Fate Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Fate Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Fate Therapeutics over time as well as its relative position and ranking within its peers.
Fate Therapeutics Earnings per Share Projection vs Actual
By analyzing Fate Therapeutics' earnings estimates, investors can diagnose different trends across Fate Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Fate Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Fate Therapeutics Ownership Allocation
Fate Therapeutics holds a total of 115.35 Million outstanding shares. The majority of Fate Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Fate Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Fate Therapeutics. Please pay attention to any change in the institutional holdings of Fate Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Fate Therapeutics Profitability Analysis
The company reported the previous year's revenue of 13.63 M. Net Loss for the year was (186.26 M) with loss before overhead, payroll, taxes, and interest of (92.41 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Fate Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Fate Therapeutics and how it compares across the competition.
About Fate Therapeutics Valuation
The stock valuation mechanism determines Fate Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Fate Therapeutics. We calculate exposure to Fate Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Fate Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 15.7 M | 16.5 M | |
| Pretax Profit Margin | (12.30) | (12.91) | |
| Operating Profit Margin | (13.88) | (14.58) | |
| Net Loss | (12.30) | (12.91) | |
| Gross Profit Margin | (1.33) | (1.39) |
Fate Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Fate Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Fate we look at many different elements of the entity such as Fate's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Fate Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Fate Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Fate Therapeutics' worth.Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |